Making U.S. biotech more competitive with China's could help rare disease patients, experts say
China is becoming a leader in biotech innovation. That offers hope to rare disease patients and presents a problem to American companies trying to save them.
TL;DR
- China's biotech sector is rapidly expanding with increased government investment, research support, and a growing number of labs and incubators.
- John Crowley, CEO of BIO, expresses concern that China's dominance in biotech could lead to control over global medicine and technology distribution.
- The number of biotech R&D companies in China has surged from a few hundred to over 4,000 in approximately ten years.
- Beijing's reduced regulatory hurdles allow drug development in China to progress faster and cheaper, attracting global researchers and manufacturers.
- The Biosecure Act was passed in the U.S. to limit federal funding for business with designated Chinese biotech companies of concern, amid worries about espionage and supply chain security.
- While China's biotech innovation is beneficial for rare disease patients in the short term, concerns exist about the potential erosion of the U.S. innovation sector.
- Calls are being made to differentiate regulatory standards for rare diseases to reduce development costs and accelerate treatment availability in the U.S.